Personalised Medicine: Dose by Design
News Aug 19, 2016
Personalised medicine holds the promise of a new approach to healthcare, tailored exactly to our individual needs. In the recent BBC Radio 4 programme Personalised Medicine: Dose by Design, a panel of experts, including Nick Lench, Congenica’s Chief Operating Officer, discussed with Vivienne Parry what the arrival of this new methodology entails for the NHS.
It was on the 26th of June 2000 that President Clinton stood in the Oval Office and announced the completion of the first survey of the entire human genome, claiming that this knowledge would prompt a revolution in “the diagnosis, prevention and treatment of most, if not all, human diseases”.
Decoding our genome opened the door to personalised medicine: by giving clinicians access to patients’ unique genetic information, it allowed them to steer away from the “one size fits all” approach of conventional medicine.
Personalised medicine brings multiple advantages. It offers the possibility of identifying the genes at the root of a disease, enabling early diagnosis, and prescription of the most effective treatment. It presents an opportunity to examine our genomes for mutations that make us more susceptible to develop certain pathologies, and make informed decisions years before the advent of the disease. It also means receiving the best drug needed to fight a specific type of tumour or knowing the precise dose of medication our bodies can process without risking adverse reactions.
All these advances are now becoming available and ready to be implemented. They are, most of the time, cost-effective and will help save the NHS money; and yet they are not readily accessible to all patients.
Vivienne Parry reflected on this dichotomy and examined the roadblocks hindering the widespread adoption of precision medicine in our current health system. With extensive experience of working within the NHS, Nick Lench was in a strong position to provide her with an insight into the challenges ahead.
Nick emphasized the need for better communication and more training on the new advances of this complex field, both for commissioners and NHS staff. Ultimately, he argues, healthcare practitioners such as cardiologists, neurologists and even those in general practice should have the opportunity to order genetic tests themselves, not just clinical geneticists.
When a patient needs a genetic test it is not always clear who should order it, how to order it and who will pay for it. The commissioning of genetics test is currently too complex, working with well-informed commissioners will be important to simplify the process and provide equity of access for all patients.
Whilst there are some hurdles to the adoption of precision medicine, Nick highlights how the growing influence of patient advocacy groups, supported by the widespread use of social media, is driving an attitude shift in healthcare.
The NHS is turning 70 in 2018; in 2000, the UK accounted for a third of the genome sequenced for the Human Genome Project. In 2012, Genomics England launched the 100,000 Genomes project, described as the UK’s “moonshot moment” in the development of personalised medicine. These projects have put us at the forefront of a new healthcare revolution that holds both promises and challenges.
Algorithm Speeds Up Medical Image Analysis 1000 TimesNews
Medical image registration is a common technique that involves overlaying two images, such as magnetic resonance imaging (MRI) scans, to compare and analyze anatomical differences in great detail. Researchers have described a machine-learning algorithm that can register brain scans and other 3-D images more than 1,000 times more quickly using novel learning techniques.
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE